Sanofi: Osteoporosis, Postmenopausal trials

The registry lists 10 Osteoporosis, Postmenopausal studies with Sanofi as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 1Phase 3 2Phase 4 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Risedronate vs Raloxifene in Hormone Replacement Therapy DiscontinuationTerminatedNCT00790101Phase 4
• A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With OsteoporosisCompletedNCT00632216Phase 4
• Satisfaction and Compliance of Risedronate in PMOCompletedNCT00549965Phase 4
• POWER Point of Care Effect on Satisfaction of TreatmentCompletedNCT00549068Phase 4
• Risedronate Sodium in Post Menopausal OsteoporosisCompletedNCT00453492Phase 4
• Risedronate in the Prevention of Osteoporosis in Postmenopausal WomenCompletedNCT00402441Phase 4
• Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal WomenCompletedNCT00358176Phase 3
• Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal WomenCompletedNCT00353080Phase 3
• Risedronate in Postmenopausal Women With Low Bone DensityCompletedNCT00351091Phase 2
• OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal WomenCompletedNCT00130403Phase 4